sales for Biogen’s multiple sclerosis (MS) franchise—which includes drugs like Tysabri and Tecfidera—declined 9% at constant currencies to a little more than $1 billion. For all of 2024 ...

Total revenue rose about 3% to $2.46 billion. Analysts had expected fourth-quarter sales of $2.41 billion. Overall sales of its multiple sclerosis drugs, which includes treatments such as Tecfidera ...

Multiple sclerosis (MS) causes neurological symptoms ... which lowers the damage they can inflict. Dimethyl fumarate (Tecfidera) is an oral capsule you take twice daily. The exact mechanism ...

Multiple sclerosis may lead to mild short-term memory loss that can affect your ability to recall information. Lifestyle changes could help you manage symptoms. Multiple sclerosis (MS) is a ...

More information: Peripartum Mental Illness in Mothers With Multiple Sclerosis and Other Chronic Diseases in Ontario, Canada, Neurology (2025). DOI: 10.1212/WNL.0000000000210170 Journal ...

But sales of the core multiple-sclerosis portfolio fell 7% to $1.070 ... tysabri biosimilar in the U.S. and generic competition for tecfidera in Europe, he said. Each of them is a disease ...

Nov. 18, 2024 — Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in ...

Botulinum toxin type A (BoNT-A), commonly known as Botox, has emerged as a promising option for managing multiple sclerosis (MS) symptoms. It may help reduce muscle contractions and spasms ...

In multiple sclerosis (MS), a person's immune system attacks the protective covering (myelin sheath) of nerve fibers in the brain and spinal cord (central nervous system). MS disease-modifying ...